Efficacy of amphotericin B in a fat emulsion for the treatment of cryptococcal meningitis in AIDS patients

Detalhes bibliográficos
Autor(a) principal: Rubio,Fernando Góngora
Data de Publicação: 2007
Outros Autores: Zanon,Jeferson Rodrigo, Almeida,Margarete Teresa Gottardo de, Góngora,Delzi Vinha Nunes de
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Brazilian Journal of Infectious Diseases
Texto Completo: http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1413-86702007000200006
Resumo: Several formulae have been developed in an attempt to reduce the toxicity of amphotericin B (AmB), but their high costs preclude widespread use. The aim of this study was to evaluate the efficacy of amphotericin B in a fat emulsion, i.e. Intralipid (AmB-IL), in 37 AIDS patients with cryptococcal meningitis (CM). We retrospectively reviewed data collected in a non-comparative open study between January 1999 and December 2001. The therapeutic cure was defined as complete resolution or improvement of the clinical symptoms or complete absence or improvement of the mycological alterations of the CSF. The outcomes were evaluated at 2 weeks, induction phase (IP), and at the end of treatment or consolidation phase (CP) with the last available CSF. Prior to the diagnosis of CM, 72% of patients had had one or more OI and 67.57% had a concomitant OI. The median CD4-cell count was 32 cells/mm³, the median leukocyte count in the CSF was 29 cells/mm³ and the median cumulative dose of AmB-IL was 1,200 mg (300-2,500). The therapeutic cure was 57.14% in the IP and 64.86% in the CP. During IP, 9 patients died (24.32%) and 4 (10.81%) during the CP (p=0.2). Thus, the overall mortality rate was 35.14%. AmB-IL, an inexpensive preparation, might be an alternative to conventional AmB. Some questions remain such as its compatibility, stability and level of toxicity. The benefit is especially important in developing countries, where no drugs other than AmB are available to treat systemic fungal infections.
id BSID-1_6fbab990d090c61db375bf816a9677ad
oai_identifier_str oai:scielo:S1413-86702007000200006
network_acronym_str BSID-1
network_name_str Brazilian Journal of Infectious Diseases
repository_id_str
spelling Efficacy of amphotericin B in a fat emulsion for the treatment of cryptococcal meningitis in AIDS patientsAmphotericin Bfat emulsioncryptococcal meningitisAIDS patientsSeveral formulae have been developed in an attempt to reduce the toxicity of amphotericin B (AmB), but their high costs preclude widespread use. The aim of this study was to evaluate the efficacy of amphotericin B in a fat emulsion, i.e. Intralipid (AmB-IL), in 37 AIDS patients with cryptococcal meningitis (CM). We retrospectively reviewed data collected in a non-comparative open study between January 1999 and December 2001. The therapeutic cure was defined as complete resolution or improvement of the clinical symptoms or complete absence or improvement of the mycological alterations of the CSF. The outcomes were evaluated at 2 weeks, induction phase (IP), and at the end of treatment or consolidation phase (CP) with the last available CSF. Prior to the diagnosis of CM, 72% of patients had had one or more OI and 67.57% had a concomitant OI. The median CD4-cell count was 32 cells/mm³, the median leukocyte count in the CSF was 29 cells/mm³ and the median cumulative dose of AmB-IL was 1,200 mg (300-2,500). The therapeutic cure was 57.14% in the IP and 64.86% in the CP. During IP, 9 patients died (24.32%) and 4 (10.81%) during the CP (p=0.2). Thus, the overall mortality rate was 35.14%. AmB-IL, an inexpensive preparation, might be an alternative to conventional AmB. Some questions remain such as its compatibility, stability and level of toxicity. The benefit is especially important in developing countries, where no drugs other than AmB are available to treat systemic fungal infections.Brazilian Society of Infectious Diseases2007-04-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersiontext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S1413-86702007000200006Brazilian Journal of Infectious Diseases v.11 n.2 2007reponame:Brazilian Journal of Infectious Diseasesinstname:Brazilian Society of Infectious Diseases (BSID)instacron:BSID10.1590/S1413-86702007000200006info:eu-repo/semantics/openAccessRubio,Fernando GóngoraZanon,Jeferson RodrigoAlmeida,Margarete Teresa Gottardo deGóngora,Delzi Vinha Nunes deeng2007-06-27T00:00:00Zoai:scielo:S1413-86702007000200006Revistahttps://www.bjid.org.br/https://old.scielo.br/oai/scielo-oai.phpbjid@bjid.org.br||lgoldani@ufrgs.br1678-43911413-8670opendoar:2007-06-27T00:00Brazilian Journal of Infectious Diseases - Brazilian Society of Infectious Diseases (BSID)false
dc.title.none.fl_str_mv Efficacy of amphotericin B in a fat emulsion for the treatment of cryptococcal meningitis in AIDS patients
title Efficacy of amphotericin B in a fat emulsion for the treatment of cryptococcal meningitis in AIDS patients
spellingShingle Efficacy of amphotericin B in a fat emulsion for the treatment of cryptococcal meningitis in AIDS patients
Rubio,Fernando Góngora
Amphotericin B
fat emulsion
cryptococcal meningitis
AIDS patients
title_short Efficacy of amphotericin B in a fat emulsion for the treatment of cryptococcal meningitis in AIDS patients
title_full Efficacy of amphotericin B in a fat emulsion for the treatment of cryptococcal meningitis in AIDS patients
title_fullStr Efficacy of amphotericin B in a fat emulsion for the treatment of cryptococcal meningitis in AIDS patients
title_full_unstemmed Efficacy of amphotericin B in a fat emulsion for the treatment of cryptococcal meningitis in AIDS patients
title_sort Efficacy of amphotericin B in a fat emulsion for the treatment of cryptococcal meningitis in AIDS patients
author Rubio,Fernando Góngora
author_facet Rubio,Fernando Góngora
Zanon,Jeferson Rodrigo
Almeida,Margarete Teresa Gottardo de
Góngora,Delzi Vinha Nunes de
author_role author
author2 Zanon,Jeferson Rodrigo
Almeida,Margarete Teresa Gottardo de
Góngora,Delzi Vinha Nunes de
author2_role author
author
author
dc.contributor.author.fl_str_mv Rubio,Fernando Góngora
Zanon,Jeferson Rodrigo
Almeida,Margarete Teresa Gottardo de
Góngora,Delzi Vinha Nunes de
dc.subject.por.fl_str_mv Amphotericin B
fat emulsion
cryptococcal meningitis
AIDS patients
topic Amphotericin B
fat emulsion
cryptococcal meningitis
AIDS patients
description Several formulae have been developed in an attempt to reduce the toxicity of amphotericin B (AmB), but their high costs preclude widespread use. The aim of this study was to evaluate the efficacy of amphotericin B in a fat emulsion, i.e. Intralipid (AmB-IL), in 37 AIDS patients with cryptococcal meningitis (CM). We retrospectively reviewed data collected in a non-comparative open study between January 1999 and December 2001. The therapeutic cure was defined as complete resolution or improvement of the clinical symptoms or complete absence or improvement of the mycological alterations of the CSF. The outcomes were evaluated at 2 weeks, induction phase (IP), and at the end of treatment or consolidation phase (CP) with the last available CSF. Prior to the diagnosis of CM, 72% of patients had had one or more OI and 67.57% had a concomitant OI. The median CD4-cell count was 32 cells/mm³, the median leukocyte count in the CSF was 29 cells/mm³ and the median cumulative dose of AmB-IL was 1,200 mg (300-2,500). The therapeutic cure was 57.14% in the IP and 64.86% in the CP. During IP, 9 patients died (24.32%) and 4 (10.81%) during the CP (p=0.2). Thus, the overall mortality rate was 35.14%. AmB-IL, an inexpensive preparation, might be an alternative to conventional AmB. Some questions remain such as its compatibility, stability and level of toxicity. The benefit is especially important in developing countries, where no drugs other than AmB are available to treat systemic fungal infections.
publishDate 2007
dc.date.none.fl_str_mv 2007-04-01
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1413-86702007000200006
url http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1413-86702007000200006
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv 10.1590/S1413-86702007000200006
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv text/html
dc.publisher.none.fl_str_mv Brazilian Society of Infectious Diseases
publisher.none.fl_str_mv Brazilian Society of Infectious Diseases
dc.source.none.fl_str_mv Brazilian Journal of Infectious Diseases v.11 n.2 2007
reponame:Brazilian Journal of Infectious Diseases
instname:Brazilian Society of Infectious Diseases (BSID)
instacron:BSID
instname_str Brazilian Society of Infectious Diseases (BSID)
instacron_str BSID
institution BSID
reponame_str Brazilian Journal of Infectious Diseases
collection Brazilian Journal of Infectious Diseases
repository.name.fl_str_mv Brazilian Journal of Infectious Diseases - Brazilian Society of Infectious Diseases (BSID)
repository.mail.fl_str_mv bjid@bjid.org.br||lgoldani@ufrgs.br
_version_ 1754209239811751936